Work

Neoadjuvant pembrolizumab in locally advanced cutaneous squamous cell carcinoma: mIF analysis

Year: 2026

Type: dataset

Abstract: Single-cell phenotype and spatial coordinate data derived from multiplex immunofluorescence (mIF) imaging of tumor specimens from a single-arm, phase II clinical trial of neoadjuvant pembrolizumab in patients with high-risk resectable cutaneous squamous cell carcinoma (cSCC) (NCT04808999). Pre-treatment core biopsies and post-treatment surgical specimens were profiled with two mIF antibody panels: Panel 1 (CD20, CD68, CD8, PD-1, panCK, PD-L1) and Panel 2 (CD163, CD68, MHCII, CD11c, panCK, PD-L1). Files include AnnData with cell typing results for pre and post treatment specimens with the corresponding UMAP results. We also include csv files cell types and registered coordinates for the two panels, these are the basis of the density analysis. AnnData with recurrent cellular neighborhood analysis from the registered images is included. Analysis code is available at https://github.com/Huang-AI4Medicine-Lab/cscc_mif_analysis.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.19665738

Authors: Galloway, Hugh, Huang, Yufei, Davar, Diwakar

Institutions: University of Pittsburgh, University of Pittsburgh Medical Center, UPMC Health System, UPMC Hillman Cancer Center

Language: English

Topic: Nonmelanoma Skin Cancer Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute